List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 206 studies with search of: "Gefitinib"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Neoplasms, Squamous Cell
Interventions: Drug: gefitinib (Iressa);   Drug: cisplatin;   Radiation: radiotherapy;   Drug: Gefitinib (Iressa)
2 Active, not recruiting Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: Gefitinib;   Drug: Gefitinib
3 Completed IRESSA™ (Gefitinib) in Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: gefitinib (IRESSA™, ZD1839)
4 Active, not recruiting Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: ZD1839 (Iressa)
5 Active, not recruiting Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Interventions: Drug: simvastatin;   Drug: gefitinib only
6 Recruiting Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib;   Drug: Placebo
7 Completed Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: ZD1839 in combination with docetaxel
8 Completed Open-Label Extension of Other SZ1839 (Iressa) Trials
Condition: Cancer
Intervention: Drug: Gefitinib (Iressa)
9 Recruiting ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Condition: Skin Cancer
Intervention: Drug: Iressa
10 Enrolling by invitation Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gefitinib retreatment
11 Active, not recruiting Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Condition: Myelogenous Leukemia, Acute
Intervention: Drug: gefitinib
12 Active, not recruiting High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Gefitinib
13 Active, not recruiting Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Neoplasms;   Fallopian Tube Cancer
Interventions: Drug: Topotecan;   Drug: Gefitinib
14 Recruiting Docetaxel With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: docetaxel OR placebo;   Drug: docetaxel OR gefitinib
15 Active, not recruiting First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Carboplatin;   Drug: Paclitaxel
16 Active, not recruiting Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Condition: Bladder Cancer
Interventions: Drug: Docetaxel;   Drug: ZD1839
17 Active, not recruiting Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Brain Metastasis
Intervention: Drug: gefitinib
18 Recruiting Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations
Condition: Non Small Cell Lung Cancer
Interventions: Drug: pemetrexed (Alimta);   Drug: Gefitinib (IRESSA)
19 Recruiting Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Gefitinib, Hydroxychloroquine
20 Active, not recruiting Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
Condition: Lung Cancer
Intervention: Drug: GEFITINIB

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services